Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia… | Phase 1 | withdrawn | Mar 4, 2021 | M.D. Anderson Cancer Center | 0% Participants | Other (stated, no rule matched) |
| NCT04148742 | Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have… | Phase 1 / Phase 2 | withdrawn | Nov 1, 2019 | Dizal Pharmaceuticals | Clinical development strategy adjustment, non-safety reason | Safety / toxicity |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in… | Phase 2 | terminated | Jan 7, 2021 | Hackensack Meridian Health | Low Accrual | Enrollment / accrual |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple… | — | terminated | May 4, 2016 | Takeda | This study was stopped 3 years early due to business reprioritization within Takeda | Sponsor / business decision |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Phase 1 | withdrawn | Aug 9, 2019 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04895917 | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis(DarPAL) | Phase 2 | terminated | May 20, 2021 | Fondazione IRCCS Policlinico San Matteo di Pavia | low patient enrollment rate | Enrollment / accrual |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic(IFM2014-01) | Phase 2 | terminated | Sep 25, 2018 | Intergroupe Francophone du Myelome | Recruitment issue, 26 patients enrolled instead of 70 initially planned | Enrollment / accrual |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including… | Phase 1 / Phase 2 | terminated | Jan 22, 2021 | Kronos Bio | Due to lack of safety and futility | Safety / toxicity |
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Phase 1 / Phase 2 | terminated | Nov 5, 2019 | Multiple Myeloma Research Consortium | Pharmaceutical support has been discontinued. | Other (stated, no rule matched) |
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive… | Phase 1 / Phase 2 | terminated | Apr 27, 2022 | Chimagen Biosciences, Ltd | Sponsor's Research and Development strategy adjustment | Sponsor / business decision |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With… | Phase 2 / Phase 3 | terminated | Dec 23, 2022 | Nektar Therapeutics | Sponsor decided to end the study | Sponsor / business decision |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | terminated | Aug 18, 2020 | Deepa Jagadeesh | Funding unavailable | Funding |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | Phase 1 | terminated | Aug 17, 2018 | Dana-Farber Cancer Institute | Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients… | Drug supply |
| NCT05096234 | 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in… | Phase 1 | terminated | Oct 27, 2021 | Stanford University | loss of sponsor support | Other (stated, no rule matched) |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory… | Phase 2 | terminated | Apr 10, 2015 | Janssen Research & Development, LLC | DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort… | Efficacy / futility |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous…(E-CELERATE) | Phase 3 | terminated | Jan 6, 2022 | Angiocrine Bioscience | Interim analysis showed lack of efficacy | Efficacy / futility |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab… | Phase 1 | withdrawn | Apr 19, 2016 | Janssen Research & Development, LLC | not stated | Not stated |
| NCT03180853 | Multiple Myeloma Patient Registry | — | terminated | Jun 8, 2017 | Janssen Scientific Affairs, LLC | Completion of study in orig timeframe not feasible considering evolving treatments for MM in US. | Other (stated, no rule matched) |
| NCT03061305 | Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors | — | terminated | Feb 23, 2017 | Strata Oncology | Sponsor's discretion to termination due to business decision. | Sponsor / business decision |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory…(AcTRESS) | Phase 1 | withdrawn | May 13, 2024 | Jules Bordet Institute | Sponsor decision | Sponsor / business decision |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated…(LOTIS-9) | Phase 2 | terminated | Dec 3, 2021 | ADC Therapeutics S.A. | The benefit-risk profile does not support continuation of the LOTIS-9 trial. | Other (stated, no rule matched) |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed…(EMBRACE) | Phase 2 | terminated | Nov 11, 2021 | Medical College of Wisconsin | Low enrollment. | Enrollment / accrual |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 22, 2022 | Ichnos Sciences SA | Business decision | Sponsor / business decision |
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After… | Phase 2 | terminated | Jan 13, 2022 | Alfred Chung, MD | Slow Accrual | Enrollment / accrual |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jan 28, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T… | Phase 1 | terminated | Aug 6, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in… | Phase 1 | terminated | Jan 25, 2022 | AstraZeneca | Due to safety reasons. | Safety / toxicity |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After… | Phase 2 | terminated | Dec 7, 2018 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Phase 1 | terminated | Jul 10, 2018 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT05276622 | Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)(PaCE-MM) | — | terminated | Mar 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Investigator left the institution. | Investigator |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent…(CHRONOS-4) | Phase 3 | terminated | Dec 10, 2015 | Bayer | Company decided to terminate this study due to study did not meet the primary endpoint. | Sponsor / business decision |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | Phase 1 | terminated | Mar 8, 2016 | Karyopharm Therapeutics Inc | sponsor decision | Sponsor / business decision |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | Phase 2 | terminated | Mar 26, 2019 | Fondazione Italiana Linfomi - ETS | Study was halted prematurely due to safety, since tocity stopping rules have been met | Safety / toxicity |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Sep 22, 2023 | Kathleen Dorritie | Closure of trial per BMS | Other (stated, no rule matched) |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute… | Phase 1 | terminated | Sep 2, 2021 | Beijing Boren Hospital | ethic commitee decision | Other (stated, no rule matched) |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | Early Phase 1 | terminated | Jan 15, 2019 | Washington University School of Medicine | Drug formulation changed, opening new trial | Other (stated, no rule matched) |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 9, 2021 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL… | Phase 3 | terminated | Feb 9, 2021 | MEI Pharma, Inc. | Discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03870451 | Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | N/A | terminated | Mar 12, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 21, 2022 | iTeos Therapeutics | Company operational decision. Decision to stop study is not due to safety or efficacy concerns | Safety / toxicity |
| NCT03311126 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle… | Phase 2 | terminated | Oct 16, 2017 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | Phase 1 / Phase 2 | withdrawn | Jan 31, 2018 | GlyPharma Therapeutics | Business decision | Sponsor / business decision |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 28, 2025source: clinicaltrials